Clinical Trial Update: Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial sponsored by the National Cancer Institute to reduce post-transplant cyclophosphamide dosing in older or unfit patients undergoing bon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• Cyclophosphamide (Cytoxan) (cyclophosphamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematologic Neoplasms | Phase 1, Phase 2 | Status: RECRUITING